Knee Nerve Cryoneurolysis and Impact on Pain After Prosthetic Surgery (Cryogenou)
Cryoneurolysis of the Saphenous Nerve or Geniculate Nerves: Impact on Postoperative Pain and Rehabilitation in Prosthetic Knee Surgery
Sponsor: Euraxi Pharma
Terminated
the recruitment rate is far too low despite an 18-month extension of the inclusion period
Other terminated trials from Euraxi Pharma
Other Knee Injuries trials with similar outcome
Listed as NCT05059535, this PHASE4 trial focuses on Knee Injuries and remains terminated or withdrawn. Sponsored by Euraxi Pharma, it has been updated 9 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Jun 2025 — Sep 2025 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE4
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
▶ Show 4 earlier versions
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE4
-
Jun 2022 — Dec 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE4
-
Oct 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Euraxi Pharma
- GCS Ramsay Santé pour l'Enseignement et la Recherche
For direct contact, visit the study record on ClinicalTrials.gov .